Companies · Other Health Care

Infinite Arthroscopy Inc., Ltd

CLEVELAND · Other Health Care

Diligence memoA one-page analyst read on Infinite Arthroscopy Inc., Ltd — recommendation, valuation, rhythm, risks.
$24.2M
Total raised · real
8
Rounds
0.3×
Latest step-up
Top 15%
Sector rank · raised
Series A
Latest stage · inferred · Thu Dec 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Infinite Arthroscopy Inc., Ltd looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.18× the median modeled value of Series A Other Health Care companies in 2022–2024 (196 peers) — value vs value, same stage and era.
  • Issuer reports $0–$1M revenue while modeled below niche peers.
Quiet
  • Last raise 18 mo ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Infinite Arthroscopy Inc., Ltd is one of 5377 Other Health Care companies tracked from CLEVELAND. By capital raised it ranks in the upper tier (ahead of 86% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$0–$1M
Issuer revenue
Rule 506(b)
Reg D exemption
7
Investors (latest)
2024-12-26
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2015-09-03 Raised $1.3M (real) Modeled valuation $31M (est)Seed2015Seed · 2017-05-19 Raised $913K (real) Modeled valuation $23M (est)Seed2017Series A · 2017-05-19 Raised $4.5M (real) Modeled valuation $91M (est)Series A2017Series A · 2017-07-01 Raised $6.2M (real) Modeled valuation $125M (est)Series A2017Series A · 2019-07-01 Raised $1.0M (real) Modeled valuation $20M (est)Series A2019Series A · 2020-01-31 Raised $670K (real) Modeled valuation $14M (est)Series A2020Series A · 2020-06-19 Raised $2.8M (real) Modeled valuation $57M (est)Series A2020Series A · 2022-12-16 Raised $7.0M (real) Modeled valuation $59M (est)Series A2022Series A · 2023-11-20 Raised $5.0M (real) Modeled valuation $30M (est)Series A2023Series A · 2024-12-26 Raised $1.7M (real) Modeled valuation $6.7M (est)Series A2024+$913K+$4.5M+$6.2M+$1.0M+$670K+$2.8M+$7.0M+$5.0M+$1.7MCumulative $31M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.3M · 2015
Seed extension$913K · 2017
Series A$4.5M · 2017
Series A extension$6.2M · 2017
Series A extension$1.0M · 2019
Series A extension$670K · 2020
Series A extension$2.8M · 2020
Series A extension$7.0M · 2022
Series A extension$5.0M · 2023
Series A extension$1.7M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$6.7M
Base estimate est.
$2.1M
Conservative case
$13.0M
Upside case
$7.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $31.2M · 2015-09-032015Seed · modeled $22.6M · 2017-05-19Series A · modeled $90.8M · 2017-05-19Series A · modeled $125.1M · 2017-07-01Series A · modeled $20.2M · 2019-07-01Series A · modeled $13.5M · 2020-01-31Series A · modeled $57.1M · 2020-06-19Series A · modeled $58.6M · 2022-12-16Series A · modeled $30.0M · 2023-11-20Series A · modeled $6.7M · 2024-12-262024
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
1.5 yr
Elapsed time used
1.5 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
12 mo
Avg between rounds
$2.6M/yr
Capital velocity
10.8 yr
On record since
2015
First round
10
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 9.9× above median
This company$24.2M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.3× of median
This company$1.7M
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$6.7M
Sector median$22.1M

Raised more than 86% of sector peers (real $). Modeled value above 27% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #177 of 196.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)CareHarmony, Inc. · Series A Raised $17.4M · modeled $145.2M (est)Dragonfly Endoscopy Inc. · Series A Raised $12.7M · modeled $142.0M (est)NuvoAir Holdings, Inc. · Series A Raised $10.7M · modeled $125.1M (est)Post Acute Recovery, Inc. · Series A Raised $14.5M · modeled $123.0M (est)Micro Interventional Devices, Inc. · Series A Raised $14.0M · modeled $119.0M (est)Etiometry Inc. · Series A Raised $15.6M · modeled $114.7M (est)SafKan, Inc. · Series A Raised $13.0M · modeled $108.5M (est)BehaVR Holdings, Inc. · Series A Raised $12.1M · modeled $102.1M (est)Outliers Inc. · Series A Raised $13.6M · modeled $101.7M (est)RevMedica, Inc. · Series A Raised $14.2M · modeled $101.2M (est)Innovoyce LLC · Series A Raised $9.9M · modeled $97.6M (est)Prixz, Inc. · Series A Raised $9.2M · modeled $97.4M (est)Infinite Arthroscopy Inc., Ltd (this company) Raised $24.2M · modeled $6.7M (est)Infinite Arthroscopy Inc., Ltd
CompanyStageRaised · realValue · estvs peer med.
CareHarmony, Inc.Series A$17.4M$145.2M3.96×
Dragonfly Endoscopy Inc.Series A$12.7M$142.0M3.87×
NuvoAir Holdings, Inc.Series A$10.7M$125.1M3.41×
Post Acute Recovery, Inc.Series A$14.5M$123.0M3.35×
Micro Interventional Devices, Inc.Series A$14.0M$119.0M3.25×
Etiometry Inc.Series A$15.6M$114.7M3.13×
SafKan, Inc.Series A$13.0M$108.5M2.96×
BehaVR Holdings, Inc.Series A$12.1M$102.1M2.78×
Outliers Inc.Series A$13.6M$101.7M2.77×
RevMedica, Inc.Series A$14.2M$101.2M2.76×
Innovoyce LLCSeries A$9.9M$97.6M2.66×
Prixz, Inc.Series A$9.2M$97.4M2.66×
Infinite Arthroscopy Inc., Ltd this companySeries A$24.2M$6.7M0.18×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.3M2015-09-03$6.3M$31.2M85%
Seed$913K2017-05-19$4.6M$22.6M90%
Series A$4.5M2017-05-19$20.5M$90.8M90%
Series A$6.2M2017-07-01$28.2M$125.1M90%
Series A$1.0M2019-07-01$4.5M$20.2M90%
Series A$670K2020-01-31$3.0M$13.5M90%
Series A$2.8M2020-06-19$12.9M$57.1M90%
Series A$7.0M2022-12-16$31.8M$58.6M90%
Series A$5.0M2023-11-20$22.7M$30.0M90%
Series A$1.7M2024-12-26$7.6M$6.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.3M2015-09-03
    • First recorded raise — entered as Seed.
    • 25 investors on this round.
  2. Seed$913K2017-05-19
    • Raised again after 20 mo — slower than the ~14 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
    • Revenue band moved $0–$1M → No revenue.
    • 8 investors on this round.
  3. Series A$4.5M2017-05-19
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.9× larger than the prior — scaling up.
  4. Series A$6.2M2017-07-01
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
  5. Series A$1.0M2019-07-01
    • Raised again after 24 mo — slower than the ~14 mo sector norm.
    • Round 6.2× smaller than the prior — bridge or down round.
  6. Series A$670K2020-01-31
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 1.5× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  7. Series A$2.8M2020-06-19
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 4.2× larger than the prior — scaling up.
    • 25 investors on this round.
  8. Series A$7.0M2022-12-16
    • Raised again after 30 mo — slower than the ~14 mo sector norm.
    • Round 2.5× larger than the prior — scaling up.
  9. Series A$5.0M2023-11-20
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
    • Revenue band moved No revenue → $0–$1M.
  10. Series A$1.7M2024-12-26
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 3.0× smaller than the prior — bridge or down round.
    • 7 investors on this round.
Intelligence
2026 ~Q1
Modeled next raise · ~12mo cadence
$1.7M
Modeled next size est.range $1.7M$2.7M
0.3×
Last step-up
$2.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Leah Brownlee3 other2020-06
Jon Serbousek2 other2017-05
Eugene Malinskiy1 other2015-09
Fred Binstock1 other2019-07
Gary Cohn1 other2019-07
Brownlee Leah2024-12
Cohn Gary2024-12
Daniel Dudley2017-05
Froimson Mark2024-12
Hanson Jeffrey2024-12
Ilya Malinskiy2017-05
Jeff Hanson2017-05
Jeffrey Hanson2020-01
Malinskiy Eugene2024-12
Mark Froimson2017-05
Michael Salerno2022-12
Salerno Michael2024-12
Serbousek Jon2024-12
Registry & provenance

Infinite Arthroscopy Inc., Ltd is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1642667
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Arthrofree LLCOther Health CarePre-Seed$200K$6.0Mnetwork2 shared operators · same sector
FPPS Holdings, LLCOther Health CareSeries A$19.0M$7.2Msame sector · same stage
Heart Test Laboratories, Inc.Other Health CareSeries A$35.1M$5.6Msame sector · same stage
SweetBio, Inc.Other Health CareSeries A$13.6M$7.7Msame sector · same stage
MetaCan, Inc.Other Health CareSeries A$13.6M$5.9Msame sector · same stage
Project Belle LLCOther Health CareSeries A$12.8M$7.4Msame sector · same stage
Lincor, Inc.Other Health CareSeries A$11.7M$6.1Msame sector · same stage
Grand River Aseptic Manufacturing, Inc.Other Health CareSeries A$11.5M$7.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Responsive Arthroscopy, Inc.Other Health CareSeries A$42.7M89%
ArthroMeda, Inc.Other Health CareSeed$49.1M87%
Arthroba, Inc.Other Health CarePre-Seed$2.4M87%
Arthrofree LLCOther Health CarePre-Seed$6.0M85%
Arthron Investments, LLCOther Health CarePre-Seed$1.2M85%
Hyalex Orthopaedics, Inc.Other Health CareSeries B$91.1M84%
Infinite Recovery Holdings, LLCOther Health CareSeed$26.1M84%
Encore Dermatology, Inc.Other Health CareSeries B$729.9M84%
Frequently asked
How much funding has Infinite Arthroscopy Inc., Ltd raised?
Infinite Arthroscopy Inc., Ltd has raised approximately $24.2M in disclosed capital across 8 recorded financing rounds, aggregated from public filings.
What is Infinite Arthroscopy Inc., Ltd's estimated valuation?
Provath's modeled valuation for Infinite Arthroscopy Inc., Ltd is approximately $6.7M (modeled range $2.1M–$13.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Infinite Arthroscopy Inc., Ltd at?
Infinite Arthroscopy Inc., Ltd's latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Dec 26.
What does Infinite Arthroscopy Inc., Ltd do and where is it based?
Infinite Arthroscopy Inc., Ltd operates in the Other Health Care sector, based in CLEVELAND.
Explore related

See where Infinite Arthroscopy Inc., Ltd sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Infinite Arthroscopy Inc., Ltd, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.